Jun 30, 2022

Revolution Medicines Q2 2022 Earnings Report

Total Revenue
$9.12M
Previous year: $8.7M
+4.8%
EPS
-$0.82
Previous year: -$0.6
+36.7%
R&D Expenses
$61M
G&A Expenses
$10.2M
Gross Profit
$6.78M
Previous year: -$37.2M
-118.2%
Cash and Equivalents
$106M
Previous year: $196M
-45.9%
Free Cash Flow
-$58.2M
Previous year: -$35.4M
+64.6%
Total Assets
$633M
Previous year: $774M
-18.2%

Revolution Medicines

Revolution Medicines